News

Experts address barriers to overcome regarding naloxone prescribing, dispensing, and utilization that they have seen in the community.

Multidisciplinary expert panel share perspectives on stigmatization and normalization of the conversation about naloxone between clinicians and patients.

Outbreaks continue around the world, including over 100,000 daily cases reported in India.

A new study supports the potential association between hydroxyurea and improved neurocognitive performance in pediatric patients.

Many believed radiocontrast exposure could be linked to long-term kidney impairment.

A dermatologist gives a broad overview of key considerations when determining a treatment course for pediatric patients.

Men with military experience were more likely to report drinking alcohol to cope than men without military experience.

Acadia stands by the safety and efficacy of pimavanserin.

The once-daily tablet is indicated for adult patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia

Changes have been made to managing acute severe ulcerative colitis during COVID-19, including intravenous steroids, rescue therapy, and surgical approaches.

New data show reduced risk of mortality, and clinical savings upward of $100,000, are linked to sometimes inaccessible substance use disorder therapies.

The oral Janus kinase 1 inhibitor abrocitinib produced similar outcomes to dupilumab in a placebo-controlled comparison for atopic dermatitis.

The pandemic forced practices to consider more virtual screening and care. A dermatologist shares perspective on what's been working as telemedicine practice.

Most patients who were treated with direct-acting antivirals for hepatitis C virus infection saw improvement in oral lichen planus symptoms, including 6 of 10 who saw complete remission.

The approval comes after Supernus resubmitted an application to address issues outlined in a FDA CRL.

High blood pressure at a younger age could forecast cardiovascular problems in adulthood.

The PCSK9 inhibitor was linked to 27% mean reduction in LDL-C over 12 weeks.

Using the ACC Expert Consensus Decision Pathway documents for the optimization of heart failure treatment and managing the increasing complexity of the disease.

A look into the role of heart failure treatment in health care and the overall provision of optimal medical therapy.

The study represents the first to examine a PPD connection to allopregnanolone.

Adam Friedman, MD, FAAD discusses how payors accelerated non-medical switching during COVID-19 and how healthcare providers can respond to new challenges. 

An interview with a phase 2 investigator on the the novel drug's potential in a field it wasn't originally designed to treat.

If approved, daridorexant would become the first sleep medication to demonstrate an improvement in sleep and daytime functioning.

The companies hope the mRNA vaccine will become the first to be granted full FDA approval.

New phase 2 data from a 24-week assessment suggest the first-in-class drug could benefit exercise and pulmonary-vascular outcomes.

Mortality rates were similar in COVID-19 patients with and without chronic inflammatory diseases.

Increasing OSA severity was associated with increasing markers of obesity.

The supplemental approval for Tyvaso comes on the basis of clinical evidence showing benefit for pulmonary and cardiovascular outcomes in adult patients.

Contrast suppression was substantially lower for patients with major depressive disorder.

A subgroup analysis from DAPA-HF show the SGLT2 inhibitor provided efficacy regardless of HFrEF patient gender.